指南与共识心血管腹部技术与安全US

基于最新美国超声心动图学会/欧洲心血管影像协会推荐,左心室舒张功能障碍对肝移植结局的影响

Impact of left ventricular diastolic dysfunction on liver transplantation outcomes based on the latest American Society of Echocardiography/European Association of Cardiovascular Imaging recommendations.
指南 / 共识 · Clin Exp Hepatol · 2021-11-26

该回顾性研究纳入400例连续肝移植患者,最终分析266例,按最新ASE/EACI推荐经胸超声心动图判定左心室舒张功能障碍(LVDD)。结果显示LVDD与5年全因死亡率无关,但非酒精性脂肪性肝炎(OR=4.43)和高血压病史(OR=2.33)是LVDD的独立预测因素。

要点

  • LVDD与肝移植后5年全因死亡率无显著影响(log-rank检验无统计学意义)。
  • 非酒精性脂肪性肝炎(OR=4.43)和高血压病史(OR=2.33)是LVDD的独立预测因素。

核心结论

  • 本研究提示,终末期肝病患者的LVDD不影响肝移植术后即刻结局或5年全因死亡率。

研究设计与样本

  • 回顾性研究,连续纳入本机构400例肝移植患者,排除经胸超声心动图数据不足56例、LVDD不确定71例及射血分数<55%者7例后,最终分析266例;采用经胸超声心动图按最新ASE/EACI推荐判定LVDD。

诊断标准与关键数值

  • LVDD判定依据最新美国超声心动图学会/欧洲心血管影像协会(ASE/EACI)推荐。
  • LVDD患者高脂血症发生率36% vs 无LVDD患者17%(p=0.003)。
  • LVDD患者高血压发生率50% vs 无LVDD患者27%(p=0.001)。
  • LVDD患者糖尿病发生率52% vs 无LVDD患者30%(p=0.003)。
  • LVDD患者非酒精性脂肪性肝炎(NASH)比例48% vs 无LVDD患者24%(p=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM OF THE STUDY: Cirrhotic cardiomyopathy encompasses systolic dysfunction, left ventricular diastolic dysfunction (LVDD), and conduction abnormalities. This study aims to investigate the impact of LVDD on mortality in patients undergoing liver transplantation (LT).

MATERIAL AND METHODS: A retrospective review of 400 consecutive patients who underwent LT at our institution was performed. Patient demographics, clinical data, and transthoracic echocardiogram (TTE) were reviewed to identify LVDD. The total cohort consisted of 266 patients after excluding patients with insufficient TTE data (n = 56), patients with indeterminate LVDD (n = 71), and patients with ejection fraction (EF) < 55% (n = 7). Statistical analysis was performed using descriptive statistics. Cox regressions with hazard ratios (HRs) and 95% confidence intervals (CI) were applied to predict 5-year all-cause mortality. Kaplan-Meier survival analysis was conducted to understand the impact of LVDD on 5-year all-cause mortality.

RESULTS: Patients with LVDD have higher incidence of hyperlipidemia (36% vs. 17%, p = 0.003), hypertension (50% vs. 27%, p = 0.001) and diabetes (52% vs. 30%, p = 0.003). In addition, patients with non-alcoholic steatohepatitis (NASH) were more likely to have LVDD (48% vs. 24%, p = 0.001). A multivariate logistic regression analysis was performed with age, body mass index (BMI), NASH, alcoholic cirrhosis, hepatitis C, history of diabetes, history of hyperlipidemia, and history of hypertension. In this multivariate logistic regression analysis, NASH (odds ratio [OR] = 4.43 [1.10-17.8], p = 0.04), and history of hypertension (OR = 2.33 [1.16-4.66], p = 0.01) were independent predictors of LVDD. The Kaplan-Meier survival analysis and multivariate Cox regression demonstrated that the presence of LVDD had no impact on 5-year all-cause mortality (log-rank test nonsignificant).

CONCLUSIONS: This study indicates that LVDD in end-stage liver disease (ESLD) patients does not affect immediate post-transplant outcomes or 5-year all-cause mortality.

来源:Clin Exp Hepatol,查看原文。版权归原作者所有。

引用

  1. Marella, Yedlapati, Kothadia, et al. Impact of left ventricular diastolic dysfunction on liver transplantation outcomes based on the latest American Society of Echocardiography/European Association of Cardiovascular Imaging recommendations. Clin Exp Hepatol. 2021. PMID: 35402726. doi:10.5114/ceh.2021.111001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。